High-flow nasal cannula oxygen therapy in post-anesthesia care unit (PACU) reduces postextubation atelectasis in patients undergoing esophageal cancer surgery: A randomized controlled trial
PLOS One · 05.05.2026 · 21 (5) · e0348511
DOI: 10.1371/journal.pone.0348511 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, online erschienen am 05.05.2026. Verfasst von Liye Han und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Pulmonary Atelectasis, Oxygen Inhalation Therapy, Airway Extubation. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Esophageal cancer surgery frequently leads to post-extubation atelectasis. The efficacy of high-flow nasal cannula (HFNC) oxygen therapy in the post-anesthesia care unit (PACU) for these patients remains unvalidated.
Methods
This randomized controlled trial enrolled 100 patients after esophageal cancer surgery, allocated to a control group (conventional oxygen therapy at 5 L/min, n = 50) or an HFNC group (heated and humidified oxygen at 40% FiO₂, 37°C, 10 L/min, n = 50). The primary outcome was the lung ultrasound score at pre-extubation (T1), 30 minutes post-intervention (T2), and before PACU discharge (T3). The secondary outcome measures included PaO 2 /FiO 2 , hypoxemia, incidence of pulmonary complications within 7 days post-intervention.
Results
The reduction in lung ultrasound score from T1 to T3 was significantly greater in the HFNC group (mean change: −5.6 points) than in the control group (mean change: −1.4 points), with a between-group difference of −4.2 points (95% CI: −4.7 to −3.7; P < 0.001). At T2 and T3, lung ultrasound score were significantly lower in the HFNC group (T2: 8.7 ± 1.2 vs. 12.7 ± 1.5; T3: 7.6 ± 1.0 vs. 11.7 ± 1.1; both P < 0.001). The HFNC group also had significantly higher PaO₂/FiO₂ ratios at T2 (325 ± 38 vs. 295 ± 35 mmHg) and T3 (340 ± 32 vs. 305 ± 30 mmHg) (both P < 0.001), and a lower incidence of hypoxic events (12.0% vs. 28.0%, P = 0.046) and 7-day postoperative pulmonary complications (10.0% vs. 36.0%, P = 0.002). No significant differences were found in sedation scores or hemodynamic parameters.
Conclusion
The utilization of HFNC oxygen therapy in the PACU may provide a safe and effective means of mitigating the severity of atelectasis subsequent to extubation, enhancing oxygenation levels, and decreasing the incidence of early pulmonary complications in patients who have undergone surgical interventions for esophageal cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
ORCID-Profile: Yun Zhu
Zitieren
APA
Han, L., Ren, D., Zhu, M., Pan, L., & Zhu, Y. (2026). High-flow nasal cannula oxygen therapy in post-anesthesia care unit (PACU) reduces postextubation atelectasis in patients undergoing esophageal cancer surgery: A randomized controlled trial. PLOS One, 21(5), e0348511. https://doi.org/10.1371/journal.pone.0348511
Vancouver
Han L, Ren D, Zhu M, Pan L, Zhu Y. High-flow nasal cannula oxygen therapy in post-anesthesia care unit (PACU) reduces postextubation atelectasis in patients undergoing esophageal cancer surgery: A randomized controlled trial. PLOS One. 2026;21(5):e0348511. doi:10.1371/journal.pone.0348511
BibTeX
@article{Han2026,
author = {Han, Liye and Ren, Die and Zhu, Mengqi and Pan, Lili and Zhu, Yun},
title = {High-flow nasal cannula oxygen therapy in post-anesthesia care unit (PACU) reduces postextubation atelectasis in patients undergoing esophageal cancer surgery: A randomized controlled trial},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {5},
pages = {e0348511},
doi = {10.1371/journal.pone.0348511}
}
EUVIMED